This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Granulomas  • Drug Therapy  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

With great interest, we read the article by Shupack and Siu¹ published in the March 2006 issue of the ARCHIVES. The authors describe a patient with a 20-month history of disseminated granuloma annulare (GA) who responded well to etanercept therapy. Unfortunately we cannot share their positive experience of etanercept treatment for this indication.

Encouraged by a report of successful infliximab treatment in disseminated GA,² we initiated etanercept therapy in 4 patients with GA unresponsive to prior conventional regimens. The patient characteristics are summarized in the Table. To evaluate the optimal dose of etanercept, both 25- and 50-mg twice-weekly applications were used. None of the patients showed any clinical improvement after 12 weeks of treatment. Additionally, no differences in dermal thickness and density were observed under 20-MHz ultrasound scanning of representative skin lesions before and after treatment. Moreover, while 2 patients had no change in clinical status, 2 . . . [Full Text of this Article]

AUTHOR INFORMATION
Alexander Kreuter, MD; Peter Altmeyer, MD; Thilo Gambichler, MD

RELATED LETTER

Resolving Granuloma Annulare With Etanercept
Jerome Shupack and Kimberly Siu
Arch Dermatol. 2006;142(3):394-395.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Failure of Etanercept Therapy in Disseminated Granuloma Annulare—Reply
Jerome L. Shupack and Kimberly Siu
Arch Dermatol. 2006;142(9):1237.
EXTRACT | FULL TEXT